摘要
目的比较亚砷酸（ATO）和全反式维甲酸（ATRA）对急性早幼粒细胞白血病（APL）的疗效及副作用。方法回顾性分析了71例APL初治患者的临床资料,根据诱导缓解治疗方案不同分为ATO组（n=41）和ATRA组（n=30）,比较两组患者的完全缓解率（CR）和达CR的时间。结果ATO组和ATRA组患者的CR率分别为97.5%和93.3%,两组相比差异无统计学意义（P〉0.05）。ATO组患者达到CR的中位时间为29 d（21-45 d）,明显短于ATRA组患者的38.5 d（24-63 d）（P〈0.001）。52.9%的ATRA组患者出现维甲酸综合征,常影响进一步治疗。结论ATO和ATRA对APL患者均有很高的诱导缓解率。ATO诱导达到CR的时间短于ATRA,不良反应更易于控制,可作为APL患者诱导缓解治疗的一线药物。
Objective To compare the efficacy and adverse effects between arsenic trioxide （ATO） and aU-trans retinoic acid （ATRA） in patients with acute promyelocytie leukemia （ APL）. Methods The clinical data of 71 patients with newly diagnosed APL were retrospectively analyzed. Two groups were classified according to the induction regimens, namely ATO group （ n = 41 ） and ATRA group （ n = 30）. The complete remission （CR） rate and the time to CR were compared between these two groups. Results The CR rate was 97.5% in ATO group and 93.3% in ATRA group （P〉0.05）. The median time to CR was 29 days （21-45 days） in ATO group, which was significantly shorter than 38.5 days （24-63 days） in ATRA group （P 〈 0. 001 ）. Retinoic acid syndrome occurred in 52.9% of patients treated with ATRA, which affected the further use of ATRA. Conclusions Both ATO and ATRA have high response rates for newly diagnosed patients with APL Compared with ATRA, ATO induction therapy has shorter time to aehieve CR and less adverse effects, and therefore may be the first-line therapy for APL.
出处
《中国医学科学院学报》
CAS
CSCD
北大核心
2009年第5期555-558,共4页
Acta Academiae Medicinae Sinicae
关键词
急性早幼粒细胞白血病
亚砷酸
全反式维甲酸
疗效
不良反应
acute promyelocytic leukemia
arsenic trioxide
all-trans retinoic acid
efficacy
adverse effect
